HC Wainwright Has Positive Outlook of BioCardia Q3 Earnings

BioCardia, Inc. (NASDAQ:BCDA) – Analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of BioCardia in a report released on Thursday, August 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.15) per share for the quarter, up from their prior estimate of ($0.18). HC Wainwright currently has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for BioCardia’s Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at ($0.39) EPS.

BCDA has been the subject of several other reports. Wall Street Zen raised shares of BioCardia from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research note on Friday, July 17th. Finally, Zacks Research raised BioCardia from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $25.00.

BioCardia Stock Up 3.8%

Shares of BioCardia stock opened at $0.98 on Monday. BioCardia has a fifty-two week low of $0.75 and a fifty-two week high of $2.29. The firm has a market cap of $11.10 million, a price-to-earnings ratio of -1.52 and a beta of 0.49. The business has a fifty day simple moving average of $0.95 and a 200-day simple moving average of $1.07.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05.

Insider Activity at BioCardia

In other news, Director Simon H. Stertzer acquired 39,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were purchased at an average price of $1.00 per share, for a total transaction of $39,000.00. Following the completion of the acquisition, the director owned 166,338 shares of the company’s stock, valued at approximately $166,338. This represents a 30.63% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders purchased 140,700 shares of company stock valued at $131,966. Insiders own 17.40% of the company’s stock.

Institutional Trading of BioCardia

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in shares of BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares during the last quarter. DRW Securities LLC bought a new position in shares of BioCardia during the 4th quarter valued at $72,000. Finally, Cetera Investment Advisers acquired a new stake in shares of BioCardia in the 2nd quarter valued at $40,000. 20.57% of the stock is owned by institutional investors.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.